期刊
CLINICAL IMMUNOLOGY
卷 139, 期 3, 页码 336-349出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.clim.2011.03.003
关键词
DC therapy; IL-10; Autoimmune diabetes; HLA transgenic mouse; NOD
类别
资金
- Seaver Institute
- JDRF [4-2007-1059]
- DERC genetic and mouse core [P32 DK 45735]
- Uehara Research Fellowship
- Ministry of Education, Culture, Science, Sports and Technology, Japan [18590990]
- Grants-in-Aid for Scientific Research [23590880, 18590990] Funding Source: KAKEN
This study was to determine whether BMDCs cultured in the presence of IL-10 (G/10-DCs) could promote T cell tolerance and prevent autoimmune diabetes in two different animal models of T1D. Our results showed that G/10-DCs suppressed both insulitis and spontaneous diabetes in NOD and HLA-DQ8/RIP-B7.1 mice. The suppression was likely to be mediated by T cells, as we found that regulatory CD4(+)CD25(+)Foxp3(+) cells were significantly increased in G/10-DC treated animals. In vivo, the G/10-DCs inhibited diabetogenic T cell proliferation; in vitro, they had reduced expression of costimulatory molecules and produced little IL-12/23 p40 or IL-6 but a large amount of IL-10 when compared with DCs matured in the presence of IL-4 (G/4-DC). We conclude that IL-10-treated DCs are tolerogenic and induce islet-directed immune tolerance, which was likely to be mediated by T regulatory cells. This non-antigen-specific DC-based approach offers potential for a new therapeutic intervention in T1D. (C) 2011 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据